Welcome to the 2nd HFpEF & HCM Drug Discovery & Development Summit
Advance Precision Medicine, Drug Development & Gene Therapy Approaches for More Curative Treatment of Heart Failure & Rare Cardiomyopathies
The highly anticipated 2nd HFpEF & HCM Drug Discovery & Development Summit is back! Uniting experts with one common goal: providing treatments for ALL patients suffering with heart failure and rare cardiomyopathies.
After an active 12 months filled with headlines including:
- “AstraZeneca presented data that showed Farxiga can reduce the risk of death in heart failure patients regardless of their ejection fraction status.”
- “With one heart failure nod already in the books, Eli Lilly and Boehringer Ingelheim’s diabetes blockbuster Jardiance just racked up a second.”
Now is the time to unite with your industry – from the commercial giants to the trailblazing pioneers – and discover new strategies for every process from discovery to early-phase development to commercialization.
Stay ahead of the curve with the 2nd HFpEF & HCM Drug Discovery & Development Summit as we bring you more speakers, more content and more exclusive insights than ever before!
World-Class Speaker Faculty Includes:
Previously Attending Companies Include:
Check out what some of our speakers have to say:
"I look forward to discussing the historical evolution in thinking about the syndrome of HFpEF and the pitfalls of continuing to think in a traditional paradigm"
Javed Butler, Director of Cardiovascular Medicine, Stony Brook Medicine
"The opportunity to meet and discuss a topic as complex as HFpEF in a dedicated meeting with ample time and with a common goal does not come often and is highly appreciated."
Ola Vedin, Global Medical Director, Heart Failure, Boehringer Ingelheim
"Developing a deeper understanding of mechanisms underlying HFpEF for development of novel therapeutics that may combat this disease."
Rachel Roth Flach, Senior Principle Scientist, Pfizer